---
id: junevity-reset
slug: junevity-reset
entity_type: commercial
status: operational
data_completeness: high
last_researched: 2025-01-27
researcher: AI Assistant
version: 2.1
name: Junevity RESET Platform - AI-Driven TF Targeting
description: AI-driven platform that identifies transcription factors driving cellular damage and develops siRNA therapeutics to reset cellular state, treating age-related diseases such as type 2 diabetes, obesity, frailty, and neurodegenerative diseases.
mission: To develop therapeutics that reset cellular state using siRNA to target transcription factors, enabling treatment of age-related diseases such as type 2 diabetes, obesity, frailty, and neurodegenerative diseases. The RESET platform uses AI to identify key transcription factors driving cellular damage and develops siRNA therapeutics to silence these pro-aging factors.
entity_data:
  focus: Development of siRNA therapeutics targeting transcription factors to reset cellular state and treat age-related diseases
  founded: 2023
  website: "https://www.junevity.com"
  industry: Biotechnology
  employees:
  as_of: 2025
  current: 11-50
  legal_name: Junevity, Inc.
  headquarters:
  city: San Francisco
  state: California
  address: San Francisco, California
  country: USA
taxonomy:
  geography: USA
  ai_technology:
  - Predictive ML/DL
  primary_focus:
  - AI-Driven Drug Discovery
  aging_approach:
  - Therapeutic Development
  target_biology:
  - Metabolic Diseases
  - General Aging/Longevity
  development_stage: Research / Preclinical
  organization_type: commercial
  organization_subtype: operational
  therapeutic_modality:
  - RNA Therapeutics
organizations:
  -
    name: Goldcrest Capital
    role: partner
    org_type: company
    role_description: Lead investor in seed funding rounds
  -
    name: Godfrey Capital
    role: partner
    org_type: company
    role_description: Investor in seed funding rounds
  -
    name: University of California, San Francisco (UCSF)
    role: partner
    org_type: institution
    role_description: "Technology licensor: Exclusive license agreement for transcription factor targeting technology"
  -
    name: Junevity
    role: primary
    org_type: company
    legal_name: Junevity, Inc.
    founded: 2023
    website: "https://www.junevity.com"
    status: operational
    role_description: Primary organization developing RESET platform and JUN_01 therapeutic
products:
  -
    name: JUN_01
    type: therapy
    status: Preclinical development
    development_stage: preclinical
links:
  -
    url: "https://blog.junevity.com/p/introducing-junevity-cell-reset-for"
    type: blog_post
    title: "Introducing Junevity: Cell Reset for Longevity with siRNA"
  -
    url: "https://venturecapital.com/news/funding-events/biotech-startup-junevity-raises-10m-for-cell-reset-therapeutics-platform-v1"
    type: news_article
    title: Biotech Startup Junevity Raises $10M for Cell Reset Therapeutics Platform
  -
    url: "https://www.junevity.com/news/press-release"
    type: press_release
    title: Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevity
  -
    url: "https://pressmediarelease.com/junevitys-pioneering-reset-platform-garners-10-million-seed-investment-to-transform-age-related-disease-treatment/"
    type: press_release
    title: "Junevity's Pioneering RESET Platform Garners $10 Million Seed Investment"
  -
    url: "https://insider.fitt.co/press-release/junevity-expands-seed-funding-to-20m-for-cell-reprogramming-with-sirna/"
    type: press_release
    title: Junevity Adds $20M for Cell Reprogramming with siRNA
  -
    url: "https://www.businesswire.com/news/home/20250213130880/en/Junevity-Raises-%2410M-to-Develop-Cell-Reset-Therapeutics-for-Longevity"
    type: press_release
    title: Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevity
  -
    url: "https://blog.junevity.com/p/junevity-expands-seed-funding-to"
    type: press_release
    title: Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNA
  -
    url: "https://www.finsmes.com/2025/02/junevity-raises-10m-in-seed-funding.html"
    type: news_article
    title: Junevity Raises $10M in Seed Funding
  -
    url: "https://www.lifespan.io/news/junevity-launches-to-develop-cell-reset-therapeutics/"
    type: news_article
    title: Junevity Launches to Develop Cell Reset Therapeutics
  -
    url: "https://www.finsmes.com/2025/12/junevity-raises-10m-expands-seed-funding-to-20m.html"
    type: news_article
    title: Junevity Raises $10M; Expands Seed Funding to $20M
  -
    url: "https://convention.bio.org/program-1/junevity"
    type: reference
    title: Junevity - BIO International Convention 2025
  -
    url: "https://www.businesswire.com/news/home/20251203837496/en/Junevity-Expands-Seed-Funding-to-%2420-Million-for-Cell-Reprogramming-with-siRNA"
    type: press_release
    title: Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNA
  -
    url: "https://app.dealroom.co/companies/junevity"
    type: reference
    title: Junevity company information, funding & investors | Dealroom.co
  -
    url: "https://pulse2.com/junevity-20-million-seed-funding/"
    type: news_article
    title: "Junevity: Seed Round Expanded To $20 Million To Advance siRNA Reprogramming Candidate Toward Clinical Trials"
  -
    url: "https://www.junevity.com/platform"
    type: website
    title: Junevity Platform - RESET Technology
  -
    url: "https://www.wsgr.com/print/v2/content/49042617/Wilson-Sonsini-Advises-Junevity-on-%2410-Million-Seed-Funding.pdf"
    type: reference
    title: Wilson Sonsini Advises Junevity on $10 Million Seed Funding
---

# Junevity RESET Platform - AI-Driven TF Targeting

## Description

AI-driven platform that identifies transcription factors driving cellular damage and develops siRNA therapeutics to reset cellular state, treating age-related diseases such as type 2 diabetes, obesity, frailty, and neurodegenerative diseases.

## Mission

To develop therapeutics that reset cellular state using siRNA to target transcription factors, enabling treatment of age-related diseases such as type 2 diabetes, obesity, frailty, and neurodegenerative diseases. The RESET platform uses AI to identify key transcription factors driving cellular damage and develops siRNA therapeutics to silence these pro-aging factors.

## Company Information

**Legal Name**: Junevity, Inc.
**Founded**: 2023
**Industry**: Biotechnology
**Employees**: {"as_of":"2025","current":"11-50"}
**Focus**: Development of siRNA therapeutics targeting transcription factors to reset cellular state and treat age-related diseases
**Website**: https://www.junevity.com

## Scientific Background

```yaml
ai_methods:
  siRNA_design:
  description: AI-assisted design of siRNA therapeutics to target identified transcription factors
  considerations:
  - Sequence optimization for target specificity
  - Off-target effect prediction and minimization
  - Delivery system compatibility
  - Stability and half-life optimization
  causal_inference:
  methods: May include causal discovery algorithms, Mendelian randomization, or other causal inference techniques (specific methods not publicly disclosed)
  purpose: Distinguish true therapeutic targets (drivers) from downstream effects (passengers)
  importance: Critical for identifying targets that will have therapeutic effects when modulated
  description: Predicts which transcription factors cause damage signals rather than merely correlating with them
  multi_omics_integration:
  purpose: Leverage complementary information from different data types to build comprehensive models of cellular regulation
  challenge: High-dimensional data integration requiring sophisticated machine learning methods
  description: Integrates genomic, transcriptomic, and epigenomic datasets to identify key regulatory nodes
  unsupervised_deep_learning:
  purpose: Identify hidden patterns and regulatory relationships that may not be apparent through traditional analysis
  advantage: Can discover novel associations without prior assumptions about specific genes or pathways
  description: Used to discover latent factors or gene modules correlating with aging phenotypes from multi-omics data
siRNA_advantages:
  dosing_frequency: siRNA therapeutics can achieve long-lasting effects with infrequent dosing (every 3-12 months)
  systemic_effects: Can reset entire pathways by targeting master regulatory nodes
  target_accessibility: Can target transcription factors that are difficult to drug with small molecules
historical_context:
  ai_in_drug_discovery_evolution:
  description: AI has increasingly been applied to drug discovery, from early applications in virtual screening to recent advances in de novo molecule design and target identification.
  junevity_contribution: "Junevity's RESET platform represents an application of AI specifically to transcription factor target identification, combining multi-omics data integration with causal inference to identify master regulatory nodes."
  siRNA_therapeutics_development:
  timeline: siRNA therapeutics have been in development since the discovery of RNAi in the 1990s. The first FDA-approved siRNA therapeutic (patisiran) was approved in 2018 for treating hereditary transthyretin-mediated amyloidosis.
  recent_advances: Recent advances in delivery systems and chemical modifications have improved siRNA stability, specificity, and therapeutic potential, enabling longer-acting formulations.
  transcription_factor_targeting_history:
  relevance: This opens new therapeutic possibilities for diseases driven by transcription factor dysregulation
  description: Transcription factors have long been recognized as important therapeutic targets, but have been difficult to drug with small molecules due to their structure and function.
  breakthrough: "siRNA technology provides a means to target transcription factors that were previously considered 'undruggable'"
biological_rationale:
  siRNA_mechanism:
  description: Small interfering RNA (siRNA) molecules can specifically silence gene expression by triggering RNA interference (RNAi) pathway. When delivered to cells, siRNA binds to complementary mRNA sequences and leads to their degradation, preventing protein production.
  delivery_considerations: "siRNA requires delivery systems to reach target cells. Junevity's approach enables dosing every six months, suggesting effective delivery and sustained effects."
  advantages_for_tf_targeting:
  - Can target any gene, including transcription factors
  - High specificity when properly designed
  - Long-lasting effects (weeks to months)
  - Enables infrequent dosing (every 3-12 months)
  cellular_aging_connection:
  description: Aging involves genome-wide shifts in gene expression and regulatory networks. Many age-related diseases are driven by dysregulated transcription factor activity that leads to chronic inflammation, metabolic dysfunction, and cellular damage.
  reset_concept: By silencing pro-aging transcription factors, the RESET platform aims to restore youthful gene expression patterns, potentially reversing age-related cellular changes and disease processes.
  transcription_factors_as_targets:
  solution: "siRNA therapeutics can silence transcription factor expression, providing a means to target these previously 'undruggable' master regulators"
  challenge: Traditional small molecule drugs often cannot effectively target transcription factors due to their structure and function
  advantages:
  - Master regulatory nodes that control entire gene networks
  - Can reset multiple pathways simultaneously
  - Address root causes of cellular dysfunction rather than symptoms
  - Enable systemic cellular reprogramming
  description: Transcription factors are master regulators of gene expression, controlling the activity of hundreds to thousands of downstream genes. They represent high-leverage intervention points in cellular regulatory networks.
reset_platform_mechanism: The RESET platform uses large-scale human disease omics data, genetic associations, and machine learning to identify transcription factors that regulate cellular damage. By targeting these transcription factors with siRNA therapeutics, the platform aims to reset cells to a healthier state, potentially reversing age-related cellular changes.
transcription_factor_targeting: Transcription factors are master regulators of gene expression. By identifying and silencing pro-aging transcription factors, the RESET platform can reprogram entire gene networks, offering a more systemic approach than single-protein inhibition.
comparison_with_other_approaches:
  vs_classical_bioinformatics:
  advantage: Systematic prioritization based on causal evidence rather than correlation alone
  description: Traditional bioinformatics approaches often yield dozens of candidate targets with unclear priority. The RESET platform uses AI to reduce this search space to the few transcription factors that matter.
  vs_single_protein_inhibition:
  advantage: More systemic approach that addresses root causes of cellular dysfunction
  description: Most drugs target single proteins, which may only address symptoms. Transcription factor targeting can reset entire pathways by modulating master regulatory nodes.
  vs_other_ai_drug_discovery_platforms:
  uniqueness: Combination of AI target identification with siRNA therapeutic modality for transcription factor targeting
  description: "While many AI platforms focus on small molecule drug discovery, Junevity's approach specifically targets transcription factors using siRNA, enabling access to previously 'undruggable' targets."
```

## Lessons Learned

### Achievements

- Successfully identified novel transcription factor targets using AI-driven RESET platform
- Demonstrated proof-of-concept in preclinical models with significant metabolic improvements
- Achieved 30% weight loss in obese mice with preservation of lean mass
- Secured $20 million in seed funding to advance toward clinical trials
- Established exclusive license with UCSF for foundational technology

### Challenges

- Early-stage company with limited public disclosure of detailed scientific data
- Novel approach requiring validation of transcription factor targeting strategy
- Need to demonstrate safety and efficacy of long-acting siRNA therapeutics in humans

### Impact on Field

Junevity represents a novel approach to treating age-related diseases by targeting transcription factors with siRNA therapeutics. The RESET platform demonstrates how AI can identify master regulatory nodes in gene networks that, when targeted, can reset entire cellular pathways. This approach offers potential advantages over single-protein inhibition by addressing root causes of cellular dysfunction. If successful, this could enable new therapeutic paradigms for metabolic diseases and aging-related conditions.

## Organizations

### Goldcrest Capital
**Role in Project**: partner
**Role Description**: Lead investor in seed funding rounds
**Organization Type**: company
**Description**: Venture capital firm
**Focus**: Biotechnology investments

### Godfrey Capital
**Role in Project**: partner
**Role Description**: Investor in seed funding rounds
**Organization Type**: company
**Description**: Venture capital firm
**Focus**: Biotechnology investments

### University of California, San Francisco (UCSF)
**Role in Project**: partner
**Role Description**: Technology licensor: Exclusive license agreement for transcription factor targeting technology
**Organization Type**: institution
**Description**: Public research university and medical center
**Focus**: Medical research, technology transfer

### Junevity
**Legal Name**: Junevity, Inc.
**Role in Project**: primary
**Role Description**: Primary organization developing RESET platform and JUN_01 therapeutic
**Organization Type**: company
**Status**: operational
**Founded**: 2023
**Website**: https://www.junevity.com
**Description**: Development of siRNA therapeutics targeting transcription factors to reset cellular state and treat age-related diseases
**Focus**: Development of siRNA therapeutics targeting transcription factors to reset cellular state and treat age-related diseases

## Locations

### Junevity San Francisco Headquarters
**Type**: headquarters
**Address**: San Francisco, California
**City**: San Francisco
**State/Region**: California
**Country**: USA
**Organizations**: Junevity

## Products

### JUN_01
**Type**: therapy
**Status**: Preclinical development
**Development Stage**: preclinical
**Role in Project**: primary
**Relationship Description**: Primary product: siRNA therapeutic targeting transcription factor for metabolic reprogramming
**Description**: siRNA therapeutic targeting a transcription factor identified by the RESET platform that regulates chronic metabolic dysfunction, insulin signaling, and appetite. First known candidate designed to reprogram metabolism using siRNA.
**Mechanism of Action**: siRNA-mediated knockdown of a transcription factor identified by the RESET platform that regulates chronic metabolic dysfunction, insulin signaling, and appetite
**Target**: Confidential transcription factor (identified via RESET platform)
**Pathway**: Transcription factor network regulating metabolic dysfunction and cellular aging
**Indications**: [
  {
    "primary": "Type 2 Diabetes",
    "secondary": [
      "Obesity"
    ]
  }
]
**Technical Details**:
```yaml
notes: JUN_01 is the first known candidate designed to reprogram metabolism using siRNA, targeting a novel transcription factor identified by the RESET platform. Expected to be the first-in-class siRNA therapeutic for metabolic reprogramming.
clinical_trials:
  -
    name: Preclinical Studies in Diabetic and Obese Mouse Models
    phase: Preclinical
    status: Completed
    results:
    dosing:
    frequency: Once every six months
    significance: "Infrequent dosing suggests long-lasting effects of siRNA treatment, which is consistent with siRNA's mechanism of action"
    patient_compliance: Infrequent dosing may improve patient compliance compared to daily medications
    therapeutic_window: Extended therapeutic window reduces need for frequent administration
    summary: Preclinical studies demonstrated significant improvements in glucose control, insulin sensitivity, and weight loss (30% reduction) with preservation of muscle mass in mouse models of diabetes and obesity. The results provide proof-of-concept that targeting transcription factors with siRNA can reset metabolic pathways and reverse disease phenotypes.
    validation:
    model_validation: Effects demonstrated in multiple mouse models (diabetic and obese models)
    safety_assessment: No adverse effects observed in preclinical studies
    replicate_experiments: Results validated through independent experiments (specific number of replicates not publicly disclosed)
    limitations:
    note: Company is preparing for IND submission and first-in-human trials, suggesting confidence in preclinical results
    publication_status: Detailed results have not yet been published in peer-reviewed journals
    quantitative_details: Specific quantitative metrics (percentages, p-values, confidence intervals, sample sizes) are not publicly disclosed as the company is in early-stage development
    obesity_model:
    note: Specific quantitative metrics (e.g., exact fat mass reduction, lean mass preservation percentages, statistical significance) are not publicly disclosed
    metabolism:
    mechanism: Transcription factor targeting appears to reset metabolic pathways, improving fat tissue function and reducing appetite
    food_intake: Reduced food intake
    adipose_tissue: Improved adipose tissue metabolism
    weight_loss:
    timeline: Weight loss achieved and maintained over extended period (specific duration not publicly disclosed)
    magnitude: 30% weight loss compared to control group
    mechanism: Improved adipose tissue metabolism and reduced food intake through transcription factor modulation
    description: Significant reduction in body weight following siRNA treatment
    body_composition:
    description: Weight loss primarily from fat mass with preservation of lean mass
    significance: Critical finding - weight loss came from fat reduction while maintaining muscle mass, which is important for metabolic health and differs from many weight loss interventions that can cause muscle loss
    metabolic_benefit: Preservation of lean mass helps maintain metabolic rate and overall health
    resistance_to_rebound:
    description: Resistance to weight regain after treatment cessation
    implication: Long-lasting effects even after treatment, consistent with the infrequent dosing schedule (once every six months)
    significance: Suggests that the intervention may have reset metabolic pathways in a durable way, rather than just temporarily suppressing appetite
    diabetes_model:
    note: Specific quantitative metrics (e.g., percentage improvement, p-values, sample sizes) are not publicly disclosed as the company is in early-stage development
    side_effects: No adverse effects observed
    glucose_control:
    details: Significant improvement in blood glucose levels following siRNA treatment targeting the identified transcription factor
    mechanism: Restoration of insulin signaling and glucose metabolism through transcription factor modulation
    description: Improved glucose control in diabetic mice
    insulin_sensitivity:
    mechanism: Targeting transcription factor that regulates insulin signaling pathways, restoring normal metabolic function
    description: Improved insulin sensitivity without weight gain or other side effects associated with insulin sensitizers
    significance: Unlike traditional insulin sensitizers (e.g., thiazolidinediones) which can cause weight gain and other adverse effects, JUN_01 improved insulin sensitivity without these drawbacks
    indication: Type 2 Diabetes and Obesity
    start_date: 2024
    publications: []
  -
    name: First-in-Human Study
    phase: Phase 1
    status: Planned
    indication: Type 2 Diabetes and Obesity
    start_date: H2 2026
    publications: []
    expected_milestone: IND submission expected in Q1 2026
regulatory_status: Pre-IND
```

## Key People

### Brent Saunders
**Title**: Advisor
**Participation Type**: advisor
**Role in Project**: Advisor
**Affiliations**: Bausch + Lomb, Junevity
**Participation Period**: 2025-present
**Expertise**: Pharmaceutical and healthcare leadership
**Biography**: CEO and Chairman of Bausch + Lomb

### Rob Cahill
**Title**: Co-founder, Chief Operating Officer
**Participation Type**: founder
**Role in Project**: Co-founder, Chief Operating Officer
**Affiliations**: Junevity
**Participation Period**: 2023-present
**Expertise**: Machine learning, operations, entrepreneurship
**Biography**: Previously machine learning researcher at UCSF, co-founder and CEO of Jhana (acquired by FranklinCovey)

### Janine Sengstack
**Title**: Co-founder, Chief Scientific Officer
**Participation Type**: founder
**Role in Project**: Co-founder, Chief Scientific Officer
**Affiliations**: Junevity
**Participation Period**: 2023-present
**Expertise**: Cellular senescence, transcription factor biology, aging research
**Biography**: PhD in cellular senescence research at UCSF, where she demonstrated the ability to reset cellular state by repressing a single transcription factor

### John Hookman
**Title**: Co-founder, CEO
**Participation Type**: founder
**Role in Project**: Co-founder, CEO
**Affiliations**: Junevity
**Participation Period**: 2023-present
**Expertise**: Pharmaceutical development, drug delivery technology
**Biography**: Previously co-founded Impel Pharmaceuticals, where he developed technology for FDA-approved nasal spray TrudhesaÂ® for acute migraine treatment

## Links

### [Introducing Junevity: Cell Reset for Longevity with siRNA](https://blog.junevity.com/p/introducing-junevity-cell-reset-for)
**Type**: blog_post
**Relevance**: secondary
**Category**: source
**Relationship Description**: Company introduction blog post
**Publisher**: Junevity
**Publication Date**: 2025-01-01
**Description**: Company introduction blog post

### [Biotech Startup Junevity Raises $10M for Cell Reset Therapeutics Platform](https://venturecapital.com/news/funding-events/biotech-startup-junevity-raises-10m-for-cell-reset-therapeutics-platform-v1)
**Type**: news_article
**Relevance**: secondary
**Category**: source
**Relationship Description**: Venture capital news coverage
**Publisher**: Venture Capital
**Publication Date**: 2025-02-01
**Description**: Venture capital news coverage

### [Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevity](https://www.junevity.com/news/press-release)
**Type**: press_release
**Relevance**: secondary
**Category**: publication
**Relationship Description**: Initial seed funding announcement
**Publisher**: Junevity
**Publication Date**: 2025-02-13
**Description**: Initial seed funding announcement

### [Junevity's Pioneering RESET Platform Garners $10 Million Seed Investment](https://pressmediarelease.com/junevitys-pioneering-reset-platform-garners-10-million-seed-investment-to-transform-age-related-disease-treatment/)
**Type**: press_release
**Relevance**: secondary
**Category**: publication
**Relationship Description**: Press release about initial seed funding
**Publisher**: Press Media Release
**Publication Date**: 2025-02-01
**Description**: Press release about initial seed funding

### [Junevity Adds $20M for Cell Reprogramming with siRNA](https://insider.fitt.co/press-release/junevity-expands-seed-funding-to-20m-for-cell-reprogramming-with-sirna/)
**Type**: press_release
**Relevance**: secondary
**Category**: publication
**Relationship Description**: Press release about seed funding expansion
**Publisher**: Fitt Insider
**Publication Date**: 2025-12-01
**Description**: Press release about seed funding expansion

### [Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevity](https://www.businesswire.com/news/home/20250213130880/en/Junevity-Raises-%2410M-to-Develop-Cell-Reset-Therapeutics-for-Longevity)
**Type**: press_release
**Relevance**: primary
**Category**: publication
**Relationship Description**: Official BusinessWire press release about initial seed funding
**Publisher**: Business Wire
**Publication Date**: 2025-02-13
**Description**: Official BusinessWire press release announcing initial $10 million seed funding and RESET platform details

### [Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNA](https://blog.junevity.com/p/junevity-expands-seed-funding-to)
**Type**: press_release
**Relevance**: primary
**Category**: publication
**Relationship Description**: Official press release about seed funding expansion
**Publisher**: Junevity
**Publication Date**: 2025-12-04
**Description**: Official press release announcing seed funding expansion to $20 million

### [Junevity Raises $10M in Seed Funding](https://www.finsmes.com/2025/02/junevity-raises-10m-in-seed-funding.html)
**Type**: news_article
**Relevance**: secondary
**Category**: source
**Relationship Description**: Initial seed funding news coverage
**Publisher**: Finsmes
**Publication Date**: 2025-02-01
**Description**: Initial seed funding news coverage

### [Junevity Launches to Develop Cell Reset Therapeutics](https://www.lifespan.io/news/junevity-launches-to-develop-cell-reset-therapeutics/)
**Type**: news_article
**Relevance**: secondary
**Category**: source
**Relationship Description**: Coverage of company launch
**Publisher**: Lifespan.io
**Publication Date**: 2025-01-01
**Description**: Coverage of company launch and RESET platform

### [Junevity Raises $10M; Expands Seed Funding to $20M](https://www.finsmes.com/2025/12/junevity-raises-10m-expands-seed-funding-to-20m.html)
**Type**: news_article
**Relevance**: secondary
**Category**: source
**Relationship Description**: News coverage of seed funding expansion
**Publisher**: Finsmes
**Publication Date**: 2025-12-01
**Description**: News coverage of seed funding expansion

### [Junevity - BIO International Convention 2025](https://convention.bio.org/program-1/junevity)
**Type**: reference
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Company presentation at BIO International Convention
**Publisher**: BIO International Convention
**Publication Date**: 2025-01-01
**Description**: Company presentation at BIO International Convention

### [Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNA](https://www.businesswire.com/news/home/20251203837496/en/Junevity-Expands-Seed-Funding-to-%2420-Million-for-Cell-Reprogramming-with-siRNA)
**Type**: press_release
**Relevance**: primary
**Category**: publication
**Relationship Description**: Official BusinessWire press release about seed funding expansion
**Publisher**: Business Wire
**Publication Date**: 2025-12-03
**Description**: Official BusinessWire press release announcing seed funding expansion to $20 million and JUN_01 development progress

### [Junevity company information, funding & investors | Dealroom.co](https://app.dealroom.co/companies/junevity)
**Type**: reference
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Company profile and funding information
**Publisher**: Dealroom
**Description**: Company profile and funding information

### [Junevity: Seed Round Expanded To $20 Million To Advance siRNA Reprogramming Candidate Toward Clinical Trials](https://pulse2.com/junevity-20-million-seed-funding/)
**Type**: news_article
**Relevance**: secondary
**Category**: source
**Relationship Description**: News coverage of seed funding expansion and clinical trial plans
**Publisher**: Pulse2
**Publication Date**: 2025-12-01
**Description**: News coverage of seed funding expansion and clinical trial plans

### [Junevity Platform - RESET Technology](https://www.junevity.com/platform)
**Type**: website
**Relevance**: primary
**Category**: source
**Relationship Description**: RESET platform technology description
**Publisher**: Junevity
**Description**: Detailed description of RESET platform technology and methodology

### [Wilson Sonsini Advises Junevity on $10 Million Seed Funding](https://www.wsgr.com/print/v2/content/49042617/Wilson-Sonsini-Advises-Junevity-on-%2410-Million-Seed-Funding.pdf)
**Type**: reference
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Legal advisory announcement
**Publisher**: Wilson Sonsini
**Publication Date**: 2025-02-01
**Description**: Legal advisory announcement

## Financials

### funding
**Amount**: $10 million USD
**Amount (Numeric)**: 10000000
**Funding Date**: 2025-12-03
**Source**: Venture Capital
**Funding Type**: Seed Extension
**Description**: Seed funding extension
**Details**:
```yaml
investors:
  - Goldcrest Capital
  - Godfrey Capital
lead_investor: Goldcrest Capital
total_seed_raised: $20 million
```

### funding
**Amount**: $10 million USD
**Amount (Numeric)**: 10000000
**Funding Date**: 2025-02-13
**Source**: Venture Capital
**Funding Type**: Seed
**Description**: Seed funding round
**Details**:
```yaml
investors:
  - Goldcrest Capital
  - Godfrey Capital
lead_investor: Goldcrest Capital
```

## Events

### License Agreement
**Date**: 2023-01-01
**Type**: partnership
**Description**: Exclusive license agreement with UCSF for technology developed by Dr. Janine Sengstack through UCSF Office of Technology Management and Advancement
**Details**:
```yaml
type: Exclusive License Agreement
asset: Transcription factor targeting technology
partner: University of California, San Francisco (UCSF)
institution: UCSF Office of Technology Management and Advancement
```

### Company Founded
**Date**: 2023-01-01
**Type**: company_founded
**Description**: Junevity founded by John Hookman, Janine Sengstack, and Rob Cahill to develop cell reset therapeutics using siRNA
**Details**:
```yaml
founders:
  - John Hookman
  - Janine Sengstack
  - Rob Cahill
```

### Seed Funding
**Date**: 2025-02-13
**Type**: funding
**Description**: Raised $10 million in seed funding led by Goldcrest Capital with participation from Godfrey Capital to develop RESET platform and advance JUN_01
**Details**:
```yaml
amount: $10 million
investors:
  - Goldcrest Capital
  - Godfrey Capital
lead_investor: Goldcrest Capital
```

### Seed Extension
**Date**: 2025-12-03
**Type**: funding
**Description**: Expanded seed funding to $20 million total with additional $10 million investment to advance JUN_01 toward clinical trials
**Details**:
```yaml
amount: $10 million
investors:
  - Goldcrest Capital
  - Godfrey Capital
lead_investor: Goldcrest Capital
total_seed_raised: $20 million
```

## Partnerships

### technology
**Date**: 2023-01-01
**Focus**: Transcription factor targeting technology licensing
**Description**: Exclusive license for technology developed by Dr. Janine Sengstack during her cellular senescence research at UCSF. The license covers transcription factor targeting technology that forms the basis of the RESET platform.
**Partner Organizations**:
- Junevity (partner)
  - Technology licensee
- University of California, San Francisco (UCSF) (partner)
  - Technology licensor
**Details**:
```yaml
type: Exclusive License Agreement
asset: Transcription factor targeting technology
partner: University of California, San Francisco (UCSF)
researcher: Dr. Janine Sengstack
institution: UCSF Office of Technology Management and Advancement
```
